Teligent competitorsClear all

Teligent's top competitors include Otonomy, Shire and Pharnext.
Teligent
Teligent
Teligent is a specialty generic pharmaceutical company.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Shire
Shire
Shire is a specialty biopharmaceutical company.
Pharnext
Pharnext
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
Founding Date
Founding Date
1977
Founding Date
2008
Founding Date
1986
Founding Date
2007
Type
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Vineland, US HQ
Mississauga, CA
Tallinn, EE
Woodbridge Township, US
Locations
San Diego, US HQ
Locations
Dublin, IE HQ
Wien, AT
Bruxelles, BE
Sofia, BG
Toronto, CA
Las Condes, CL
see more
Locations
Issy-les-Moulineaux, FR HQ
Employees
Employees
1893% increase
Employees
498% decrease
Employees
23,044
Employees
4319% increase
Valuation ($)
Valuation ($)
29.5 m
Valuation ($)
73.6 m
Valuation ($)
54.8 b
Valuation ($)
123.1 m
Twitter followers
Twitter followers
94
Twitter followers
233
Twitter followers
7.7 k
Twitter followers
1.6 k
Alexa Website Rank
Alexa Website Rank
1321607
Alexa Website Rank
318925
Alexa Website Rank
333836
Alexa Website Rank
1335066

Financial

Revenue (est.)
Revenue (est.)
$158.3m (FY, 2018)
Revenue (est.)
$745k (FY, 2018)
Revenue (est.)
£43m (FY, 2018)
Revenue (est.)
N/A
Cost of goods
Cost of goods
$43.5m (FY, 2018)
Cost of goods
$946k (FY, 2018)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$114.8m (FY, 2018)
Gross profit
($201k) (FY, 2018)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($36.3m) (FY, 2018)
Net income
($50.4m) (FY, 2018)
Net income
£3.4m (FY, 2018)
Net income
N/A

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
7 (FY, 2017)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
10 (FY, 2017)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
15 (FY, 2017)
Phase III Trials Products
N/A
Preclinical Phase Products
Preclinical Phase Products
N/A
Preclinical Phase Products
1 (FY, 2016)
Preclinical Phase Products
35 (FY, 2017)
Preclinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
$ 16.1m
Total funding raised
$ 153.4m
Total funding raised
N/A
Total funding raised
$ 10.6m
For sources of this data, please see the company profile

View company profiles

Otonomy
HQ
San Diego, US
Employees
49↓ 8% decrease

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Shire
HQ
Dublin, IE
Employees
23,044

Shire is a specialty biopharmaceutical company.

View company
Pharnext
HQ
Issy-les-Moulineaux, FR
Employees
43↑ 19% increase

Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.

View company